Introduction: Effective management of type 2 diabetes requires sustained glycemic control over many years, which can be particularly challenging for elderly people. This sub-analysis of the A(1)chieve study evaluated the clinical safety and effectiveness of biphasic insulin aspart 30 in 3 age-groups (<= 40, <40-65, and [65 years) of previously insulin-experienced and insulin-naive people with type 2 diabetes. Methods: A1chieve was an international, multicenter, prospective, open-label, non-interventional, 24-week study in people with type 2 diabetes who had been receiving anti-diabetes medication before starting, or switching to, therapy with biphasic insulin aspart 30, insulin detemir or insulin aspart (alone or in combination) in routine clinical practice. This sub-analysis evaluated clinical safety and effectiveness of biphasic insulin aspart 30 (+/- oral glucose-lowering drugs) in different age-groups. Results: Data on 40,122 participants were included. In all age-groups, the proportion of participants experiencing any hypoglycemia, major hypoglycemia or nocturnal hypoglycemia was significantly reduced from baseline, except for the following in insulin-naive patients: a significant increase in any hypoglycemia in patients aged [65 years; no change in any hypoglycemia, major hypoglycemia, and nocturnal hypoglycemia in patients aged >40-65, <= 40, and [65 years, respectively. Significant improvements at 24 weeks vs. baseline were observed in insulin-experienced and insulin-naive participants for: glycated hemoglobin (change from baseline ranged from -1.8% to -2.4%); fasting plasma glucose (from 3.0 to -4.3mmol/l); post-breakfast post-prandial plasma glucose (from -4.1 to -6.5 mmol/l); and health-related quality of life (HRQoL). Sixteen serious adverse drug reactions were reported. Conclusion: After 24-week treatment with biphasic insulin aspart 30, all age-groups of insulin-experienced and insulin-naive patients experienced significantly improved glycemic control and HRQoL; incidence of hypoglycemia was generally reduced. The tolerability and effectiveness of biphasic insulin aspart 30 may benefit all age-groups.